Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Stanford University
Dana-Farber Cancer Institute
City of Hope Medical Center
M.D. Anderson Cancer Center
Mayo Clinic
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
Eli Lilly and Company
AbbVie
Northwestern University
Case Comprehensive Cancer Center
Astex Pharmaceuticals, Inc.
University of Chicago
Pfizer
Fox Chase Cancer Center
Ipsen
OHSU Knight Cancer Institute
Prelude Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Taiga Biotechnologies, Inc.
Medigene AG
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
University of Wisconsin, Madison
University of Washington
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
California Cancer Consortium
Massachusetts General Hospital
University of Louisville
Washington University School of Medicine
Yale University
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
University of Massachusetts, Worcester
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Children's Oncology Group
Synta Pharmaceuticals Corp.